Date Filed | Type | Description |
09/28/2023 |
8-K
| Quarterly results |
08/15/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
08/15/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
08/15/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
08/10/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
08/09/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
08/04/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
08/01/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
07/03/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/05/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
05/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
04/20/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
03/08/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
02/14/2023 |
SC 13G/A
| Point72 Asset Management, L.P. reports a 0% stake in Minerva Neurosciences, Inc. |
02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 3.6% stake in Minerva Neurosciences Inc. |
02/01/2023 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 22.5% stake in MINERVA NEUROSCIENCES, INC. |
12/28/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
12/16/2022 |
8-K
| Quarterly results |
12/02/2022 |
8-K
| Quarterly results |
11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
10/17/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
09/26/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
09/14/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
09/09/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and... |
08/23/2022 |
SC 13G
| Point72 Asset Management, L.P. reports a 8.8% stake in Minerva Neurosciences, Inc. |
08/22/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
08/09/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
06/17/2022 |
8-K
| Quarterly results |
06/15/2022 |
8-K
| Quarterly results |
05/04/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
04/26/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/26/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/14/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
|